Market Research Logo

Global Diabetes Management Devices Market 2017-2021

Global Diabetes Management Devices Market 2017-2021

About Diabetes Management Devices

Diabetes management devices include insulin delivery systems and blood glucose monitoring devices, which are used to treat diabetes effectively and efficiently with fewer side effects. Diabetes (type 1 and type 2) is a chronic disease condition, which occurs due to glucose impairment. The major factors contributing to the disease include obesity, urbanization, sedentary lifestyle, smoking, an elevated level of cholesterols, and hypertension. Vendors in this market are offering high-end insulin delivery systems (less invasive, sleek, pocket-sized, and portable devices) and continuous glucose monitoring systems, which are highly efficient and have user-friendly features.

Technavio’s analysts forecast the global diabetes management devices market to grow at a CAGR of 8.08% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global diabetes management devices market for 2017-2021. To calculate the market size, the report considers the sales from insulin delivery systems and continuous blood glucose monitoring systems.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Diabetes Management Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Abbott
  • Dexcom
  • F. Hoffmann-La Roche
  • LifeScan
  • Medtronic
Other prominent vendors
  • AgaMatrix
  • Animas
  • ARKRAY
  • Ascensia Diabetes Care
  • B. Braun Melsungen
  • BD
  • Beta Bionics
  • Bigfoot Biomedical
  • BIONIME USA
  • CellNovo
  • Eli Lilly
  • iHealth Labs
  • Insulet
  • Nemaura Medical
  • Nipro
  • Nova Biomedical
  • Novo Nordisk
  • Panasonic Healthcare
  • Prodigy Diabetes Care
  • Sanofi
  • Senseonics
  • Tandem Diabetes Care
  • Trividia Health
  • TypeZero Technologies
  • Valeritas
  • WellDoc
Market driver
  • Rising global burden of diabetes
  • For a full, detailed list, view our report
Market challenge
  • Prohibitive cost of the diabetes care devices
  • For a full, detailed list, view our report
Market trend
  • Growing focus on artificial pancreas
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Diabetes Management Devices Market 2017-2021

Technavio recognizes the following companies as the key players in the global diabetes management devices market: Abbott, Dexcom, F. Hoffmann-La Roche, LifeScan, and Medtronic

Other Prominent Vendors in the market are: AgaMatrix, Animas, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, BD, Beta Bionics, Bigfoot Biomedical, BIONIME USA, CellNovo, Eli Lilly, iHealth Labs, Insulet, Nemaura Medical, Nipro, Nova Biomedical, Novo Nordisk, Panasonic Healthcare, Prodigy Diabetes Care, Sanofi, Senseonics, Tandem Diabetes Care, Trividia Health, TypeZero Technologies, Valeritas, and WellDoc.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Growing focus on artificial pancreas. Diabetes is a serious condition that develops due to the absence of insulin, which is secreted by islets of Langerhans in the pancreas. The artificial pancreas is the newest technology that helps people to manage diabetes automatically by controlling their blood glucose levels by providing the substitute endocrine functionality of healthy pancreas. The launch of the first artificial pancreas by Medtronic has been one of the most revolutionary advances in medical device history. It is a clinically efficient, next-generation insulin pump technology with continuous monitoring of glucose. It has fewer complications and offers greater ability to live without complications.”

According to the report, one of the major drivers for this market is Rising global burden of diabetes. Diabetes is a chronic disease, which occurs when the body cannot use insulin effectively or when the pancreas does not produce enough insulin. Hyperglycemia or increased blood sugar can result in severe damage or complication, which may become life-threatening to the individual if left untreated.

Further, the report states that one of the major factors hindering the growth of this market is Prohibitive cost of the diabetes care devices. Diabetes is a condition, which requires continuous monitoring of the blood glucose levels and insulin treatment. Vendors are offering novel CGM devices and insulin delivery systems, which improve the patient’s quality of life. The devices offer readings with minimal or reduced finger sticks, thereby generating accurate results. However, the novel designs are too expensive for a normal diabetic patient to afford and use, especially in case of developing countries. Traditional insulin therapy involves the use of insulin syringes. However, with the recent technical advances, vendors are offerings insulin jet injectors, insulin pens, insulin patches, and implantable insulin devices, which are highly expensive. For instance, Medtronic’s offering, the MiniMed 670G, has an estimated cost of around $5,000-$8,000 with the annual cost of disposable sensors, which cost another few thousand dollars. Also, the insulin jet injectors, which cost around $300-$700, are costlier when compared with insulin pens.

Companies Mentioned

Abbott, Dexcom, F. Hoffmann-La Roche, LifeScan, Medtronic, AgaMatrix, Animas, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, BD, Beta Bionics, Bigfoot Biomedical, BIONIME USA, CellNovo, Eli Lilly, iHealth Labs, Insulet, Nemaura Medical, Nipro, Nova Biomedical, Novo Nordisk, Panasonic Healthcare, Prodigy Diabetes Care, Sanofi, Senseonics, Tandem Diabetes Care, Trividia Health, TypeZero Technologies, Valeritas, and WellDoc.

  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Market outline
      • Table Types of diabetes
      • Table Risk factors for diabetes
  • Market landscape
    • Market overview
      • Table Global diabetes management devices market 2016-2021 ($ millions)
    • Five forces analysis
      • Table Five forces
  • Market segmentation by product
    • Table Segmentation of global diabetes management devices by product 2016
    • Table Global diabetes management devices market analysis by product 2016
    • Table Global diabetes management devices market by product 2016 and 2021 (%)
    • Table Global diabetes management devices market by product 2016 and 2021 ($ millions)
    • Table Global diabetes management devices market share by product 2016-2021 (%)
    • Comparison by product
      • Table Comparison by product
    • Insulin delivery systems
      • Table Global insulin delivery systems market 2016-2021 ($ millions)
      • Table Global insulin delivery systems market: Year-over-year (YoY) growth 2017-2021 (%)
    • Blood glucose monitoring devices
      • Table Global blood glucose monitoring devices market 2016-2021 ($ millions)
      • Table Global blood glucose monitoring devices market: YoY growth 2017-2021 (%)
    • Market opportunity by product
      • Table Global diabetes management devices market: Opportunity by product
  • Market segmentation by end-users
    • Table Global diabetes management devices market by end-users 2016 (%)
    • Hospitals
    • Specialty diabetes clinics
    • Home care settings
    • Others
  • Regional landscape
    • Table Global diabetes management devices market analysis by geography 2016
    • Table Segmentation of global diabetes management devices market by geography 2016 and 2021 ($ millions)
    • Table Segmentation of global diabetes management devices market by geography 2016 and 2021 (%)
    • Geographical segmentation
      • Table Global diabetes management devices market share by geography 2016-2021 (%)
    • Regional comparison
      • Table Global diabetes management devices market: Regional comparison
    • Diabetes management devices market in Americas
      • Table Diabetes management devices market in Americas 2016-2021 ($ millions)
      • Table Diabetes management devices market in Americas: YoY growth 2017-2021 (%)
      • Table Top three countries in Americas
    • Diabetes management devices market in EMEA
      • Table Diabetes management devices market in EMEA 2016-2021 ($ millions)
      • Table Diabetes management devices market in EMEA: YoY growth 2017-2021 (%)
      • Table Top three countries in EMEA
    • Diabetes management devices market in APAC
      • Table Diabetes management devices market in APAC 2016-2021 ($ millions)
      • Table Diabetes management devices market in APAC: YoY growth 2017-2021 (%)
      • Table Top three countries in APAC
    • Market opportunity by region
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Prevalence of diabetes 2000 and 2030 (millions)
      • Table Recent product launches
    • Market challenges
      • Table Product recalls
  • Market trends
    • Growing focus on artificial pancreas
      • Table Pipeline products
    • Increasing focus on home care settings
    • Technological advancements/improvements
  • Vendor landscape
    • Competitive scenario
    • Key news
    • M&A
  • Vendor analysis
    • Vendor overview
    • Abbott
      • Table Abbott: Key highlights
      • Table Abbott: Strength assessment
      • Table Abbott: Strategy assessment
      • Table Abbott: Opportunity assessment
    • Dexcom
      • Table Dexcom: Key highlights
      • Table Dexcom: Strength assessment
      • Table Dexcom: Strategy assessment
      • Table Dexcom: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • LifeScan
      • Table LifeScan: Key highlights
      • Table LifeScan: Strength assessment
      • Table LifeScan: Strategy assessment
      • Table LifeScan: Opportunity assessment
    • Medtronic
      • Table Medtronic: Key highlights
      • Table Medtronic: Strength assessment
      • Table Medtronic: Strategy assessment
      • Table Medtronic: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report